---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-081680"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-07-23T23:59:59+00:00"
generated_at: "2026-05-31T17:50:22.670088+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cellectar's iopofosine I 131 hits primary endpoint in WM pivotal study; 56.4% MRR

## Summary
- CLOVER WaM study met primary endpoint: MRR 56.4% (95% CI 42-67%) vs 20% agreed target.
- ORR of 80% and disease control rate 98.2% in heavily pre-treated WM patients (median 4 prior therapies).
- 78% of major responders progression-free at 18 months; median DoR not reached.
- Company plans to submit NDA in Q4 2024 and seek priority review.
- Preliminary cash and equivalents ~$25.9M as of June 30, 2024 (unaudited, subject to change).

## SEC filing metadata
- accession: 0001104659-24-081680
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-07-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924081680/0001104659-24-081680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924081680/tm2419979d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-081680
- JSON: https://secwatch.observer/filing/0001104659-24-081680.json
- Plain text: https://secwatch.observer/filing/0001104659-24-081680.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.